REMI (Remedent) Cyclically Adjusted Revenue per Share: $0.00 (As of Dec. 2020)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

REMI Remedent Inc REMI
12 GF Score
Price $0.00
View Full Analysis

What is Remedent Cyclically Adjusted Revenue per Share?

Remedent REMI +16.67% 12 Cyclically Adjusted Revenue per Share is $0.00 as of Dec. 2020. GuruFocus rates REMI with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Remedent's adjusted revenue per share for the three months ended in Dec. 2020 was $0.017. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-15), Remedent's current stock price is $0.0007. Remedent's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2020 was $0.00. Remedent's Cyclically Adjusted PS Ratio of today is .


Remedent  (OTCPK:REMI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Remedent Cyclically Adjusted Revenue per Share Related Terms


Remedent Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Remedent's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remedent Cyclically Adjusted Revenue per Share Chart

Remedent Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Remedent Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

REMI vs SECI, RSCF, OZSC: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Remedent's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remedent Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Remedent's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Remedent's Cyclically Adjusted PS Ratio falls into.


REMI
12GF Score
Remedent Inc REMI
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remedent Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Remedent's adjusted Revenue per Share data for the three months ended in Dec. 2020 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=0.017/108.5107*108.5107
=0.017

Current CPI (Dec. 2020) = 108.5107.

Remedent Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201103 0.140 94.666 0.160
201106 0.150 95.508 0.170
201109 0.165 95.795 0.187
201112 0.105 96.360 0.118
201203 0.063 97.847 0.070
201206 0.021 97.659 0.023
201209 0.022 98.432 0.024
201212 0.036 98.511 0.040
201303 0.068 98.937 0.075
201306 0.035 99.215 0.038
201309 0.038 99.314 0.042
201312 0.043 99.462 0.047
201403 0.013 99.819 0.014
201406 0.046 99.482 0.050
201409 0.043 99.195 0.047
201412 0.042 99.086 0.046
201503 0.049 99.423 0.053
201506 0.041 100.107 0.044
201509 0.035 100.245 0.038
201512 0.033 100.572 0.036
201603 0.029 101.653 0.031
201606 0.031 102.267 0.033
201609 0.031 102.118 0.033
201612 0.030 102.614 0.032
201703 0.027 103.972 0.028
201706 0.040 103.902 0.042
201709 0.034 104.170 0.035
201712 0.037 104.804 0.038
201803 0.024 105.419 0.025
201806 0.022 106.063 0.023
201809 0.017 106.618 0.017
201812 0.021 107.252 0.021
201903 0.020 107.876 0.020
201906 0.016 107.896 0.016
201909 0.012 107.470 0.012
201912 0.013 108.065 0.013
202003 0.013 108.550 0.013
202006 0.011 108.540 0.011
202009 0.016 108.441 0.016
202012 0.017 108.511 0.017

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Remedent (REMI) has a Cyclically Adjusted Revenue per Share of $0.00 as of Dec. 2020. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Remedent and its competitors.
Is Remedent's Cyclically Adjusted Revenue per Share too high?
Remedent's current Cyclically Adjusted Revenue per Share is $0.00. Overall, Remedent has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Remedent's Cyclically Adjusted Revenue per Share compare to SECI and RSCF?
Remedent's Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Remedent and its competitors. Remedent's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remedent stock overvalued right now?
Remedent (REMI) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Remedent's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Remedent (REMI), the current Cyclically Adjusted Revenue per Share is $0.00 as of Dec. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Remedent Business Description

Address Zuiderlaan 1-3, Bus 8, Ghent, BEL, 9000
Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States.
12GF Score

Get the complete analysis for REMI

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price